Ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma: clinical outcomes and prognostic factors
Ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma: clinical outcomes and prognostic factors
复制标题
超声引导下经皮微波消融治疗肝细胞癌：临床结果和预后因素。
DOI：
10.1007/s00432-016-2266-5
复制
发表时间：
2017-01-01
影响因子：
3.6
通讯作者：
Zhai, Bo
中科院分区：
文献类型：
--
作者：
Ma, Sicong;Ding, Min;Zhai, Bo
目的 本研究的目的是评估超声引导经皮微波消融（US-guided PMWA）治疗肝细胞癌（HCC）的临床效果，并分析预后因素。 材料与方法 433例HCC患者（直径5 cm，血清AFP水平较高（>20 ng/ml））的治疗和生存参数是无进展生存（PFS）的显着不利预后因素。累积 1 年、2 年和 3 年总生存 (OS) 率分别为 83.5%、66.1 % 和 58.7%（中位：43 个月）。肿瘤直径 >5 cm 和血清 AFP >400 ng/ml 是 OS 的显着不利预测因素。 结论 PMWA 在 HCC 患者中耐受性良好，并且能够提供高肿瘤数量、肿瘤大小和 AFP。水平是患者 PFS 的显着预测因素，而肿瘤大小和 AFP 水平是 OS 的显着预测因素。
Objective The aim of this study was to evaluate the clinical outcomes of ultrasound-guided percutaneous microwave ablation (US-guided PMWA) for the treatment of hepatocellular carcinoma (HCC) with the analysis of prognostic factors.Materials and methods The treatment and survival parameters of 433 patients with HCC (5 cm in diameter, and higher serum AFP level (>20 ng/ml) were significant unfavorable prognosticators of progression-free survival (PFS). The cumulative 1-, 2-, and 3-year overall survival (OS) rates were 83.5, 66.1, and 58.7 %, respectively (median: 43 months). Tumor >5 cm in diameter and serum AFP >400 ng/ml were significant unfavorable prognosticators of OS.Conclusions PMWA is well tolerated in HCC patients and capable of offering high CA rate. Tumor number, tumor size, and AFP level were significant prognosticators of patients' PFS, whereas tumor size and AFP level were significant prognosticators of OS.